Cognitive Impairment in Thalassemia and Associated Factors

Dement Geriatr Cogn Disord. 2022;51(2):128-134. doi: 10.1159/000522655. Epub 2022 Mar 23.

Abstract

Introduction: Patients with thalassemia increase the risk of developing cognitive impairment. Chronic anemia, oxidative stress from excess iron, and hypercoagulable state were related to this condition. The study regarding its prevalence and the associated factor in Southeast Asia is limited. Therefore, the study aimed to investigate the prevalence of cognitive impairment and associated factors.

Methods: This was a cross-sectional study of thalassemic patients aged 18 years or more at the Hematology Clinic of Srinagarind Hospital, Khon Kaen University, Thailand, from January to May 2021. The Thai version of the Mini-Cog test was used to determine the presence of cognitive impairment. The clinical and laboratory parameters indicated as potential risk factors for dementia were evaluated in all patients. A stepwise logistic regression analysis was used to determine the associated risk factors for cognitive impairment.

Results: Among 150 patients, cognitive impairment was found in 40 patients (26.7%). Age per 10-year increase (adjusted odds ratio [AOR] of 1.6), no iron chelation therapy (AOR of 9.8), current smoking (AOR of 5.0), hemoglobin (Hb) (AOR of 0.63), and ferritin (AOR of 1.0001) were independent factors associated with cognitive impairment.

Conclusions: The prevalence of cognitive impairment was high among thalassemic patients. Increasing age, low Hb, iron overload, and current smoking were significant associated factors with cognitive impairment. Screening for dementia in these patients is recommended, particularly in patients with high-risk factors.

Keywords: Dementia; Risk factors; Thalassemia; The Mini-Cog test.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cognitive Dysfunction* / epidemiology
  • Cross-Sectional Studies
  • Dementia*
  • Humans
  • Thailand / epidemiology
  • Thalassemia* / complications
  • Thalassemia* / drug therapy
  • Thalassemia* / epidemiology